458 related articles for article (PubMed ID: 7895772)
1. Identification of antagonists for melanocortin MC3, MC4 and MC5 receptors.
Adan RA; Oosterom J; Ludvigsdottir G; Brakkee JH; Burbach JP; Gispen WH
Eur J Pharmacol; 1994 Nov; 269(3):331-7. PubMed ID: 7895772
[TBL] [Abstract][Full Text] [Related]
2. Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors.
Hruby VJ; Lu D; Sharma SD; Castrucci AL; Kesterson RA; al-Obeidi FA; Hadley ME; Cone RD
J Med Chem; 1995 Sep; 38(18):3454-61. PubMed ID: 7658432
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of melanocortin peptides on neural melanocortin receptors.
Adan RA; Cone RD; Burbach JP; Gispen WH
Mol Pharmacol; 1994 Dec; 46(6):1182-90. PubMed ID: 7808440
[TBL] [Abstract][Full Text] [Related]
4. Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat.
Adan RA; Szklarczyk AW; Oosterom J; Brakkee JH; Nijenhuis WA; Schaaper WM; Meloen RH; Gispen WH
Eur J Pharmacol; 1999 Aug; 378(3):249-58. PubMed ID: 10493100
[TBL] [Abstract][Full Text] [Related]
5. Selectivity of [Phe-I7], [Ala6], and [D-Ala4,Gln5,Tyr6] substituted ACTH(4-10) analogues for the melanocortin receptors.
Schiöth HB; Muceniece R; Wikberg JE
Peptides; 1997; 18(5):761-3. PubMed ID: 9213373
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the melanocyte stimulating hormones on food intake. Lack Of evidence to support a role for the melanocortin-3-receptor.
Abbott CR; Rossi M; Kim M; AlAhmed SH; Taylor GM; Ghatei MA; Smith DM; Bloom SR
Brain Res; 2000 Jun; 869(1-2):203-10. PubMed ID: 10865075
[TBL] [Abstract][Full Text] [Related]
7. Melanin-concentrating hormone, melanocortin receptors and regulation of luteinizing hormone release.
Murray JF; Adan RA; Walker R; Baker BI; Thody AJ; Nijenhuis WA; Yukitake J; Wilson CA
J Neuroendocrinol; 2000 Mar; 12(3):217-23. PubMed ID: 10718917
[TBL] [Abstract][Full Text] [Related]
8. Long term orexigenic effect of a novel melanocortin 4 receptor selective antagonist.
Skuladottir GV; Jonsson L; Skarphedinsson JO; Mutulis F; Muceniece R; Raine A; Mutule I; Helgason J; Prusis P; Wikberg JE; Schiöth HB
Br J Pharmacol; 1999 Jan; 126(1):27-34. PubMed ID: 10051117
[TBL] [Abstract][Full Text] [Related]
9. Effects of melanocortin receptor ligands on thyrotropin-releasing hormone release: evidence for the differential roles of melanocortin 3 and 4 receptors.
Kim MS; Small CJ; Russell SH; Morgan DG; Abbott CR; alAhmed SH; Hay DL; Ghatei MA; Smith DM; Bloom SR
J Neuroendocrinol; 2002 Apr; 14(4):276-82. PubMed ID: 11963824
[TBL] [Abstract][Full Text] [Related]
10. Further pharmacological characterization of the selective melanocortin 4 receptor antagonist HS014: comparison with SHU9119.
Schiöth HB; Muceniece R; Mutulis F; Bouifrouri AA; Mutule I; Wikberg JE
Neuropeptides; 1999 Jun; 33(3):191-6. PubMed ID: 10657491
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of intracellular free calcium in GH3 cells by gamma3-melanocyte-stimulating hormone. Involvement of a novel melanocortin receptor?
Langouche L; Roudbaraki M; Pals K; Denef C
Endocrinology; 2001 Jan; 142(1):257-66. PubMed ID: 11145589
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of melanocortin receptor subtypes by radioligand binding analysis.
Schiöth HB; Muceniece R; Wikberg JE; Chhajlani V
Eur J Pharmacol; 1995 Feb; 288(3):311-7. PubMed ID: 7774675
[TBL] [Abstract][Full Text] [Related]
13. Evidence that alpha-MSH induced grooming is not primarily mediated by any of the cloned melanocortin receptors.
Sanchez MS; Celis ME; Schiöth HB
Neuropeptides; 2000 Apr; 34(2):77-82. PubMed ID: 10985923
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel melanocortin4 receptor selective MSH analogues.
Schiöth HB; Mutulis F; Muceniece R; Prusis P; Wikberg JE
Br J Pharmacol; 1998 May; 124(1):75-82. PubMed ID: 9630346
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of behavioural effects of neural melanocortin receptor antagonists injected ICV and in VTA in rats.
Klusa V; Svirskis S; Opmane B; Muceniece R; Skujins A; Mutulis F; Wikberg JE; Schiöth HB
Neuropeptides; 1998 Dec; 32(6):573-80. PubMed ID: 9920457
[TBL] [Abstract][Full Text] [Related]
16. Agouti antagonism of melanocortin-4 receptor: greater effect with desacetyl-alpha-melanocyte-stimulating hormone (MSH) than with alpha-MSH.
Mountjoy KG; Willard DH; Wilkison WO
Endocrinology; 1999 May; 140(5):2167-72. PubMed ID: 10218968
[TBL] [Abstract][Full Text] [Related]
17. Asp10 in Lys-gamma2-MSH determines selective activation of the melanocortin MC3 receptor.
Oosterom J; Burbach JP; Gispen WH; Adan RA
Eur J Pharmacol; 1998 Jul; 354(1):R9-11. PubMed ID: 9726642
[TBL] [Abstract][Full Text] [Related]
18. Melanocortins and cardiovascular regulation.
Versteeg DH; Van Bergen P; Adan RA; De Wildt DJ
Eur J Pharmacol; 1998 Oct; 360(1):1-14. PubMed ID: 9845266
[TBL] [Abstract][Full Text] [Related]
19. Melanocortin antagonists define two distinct pathways of cardiovascular control by alpha- and gamma-melanocyte-stimulating hormones.
Li SJ; Varga K; Archer P; Hruby VJ; Sharma SD; Kesterson RA; Cone RD; Kunos G
J Neurosci; 1996 Aug; 16(16):5182-8. PubMed ID: 8756446
[TBL] [Abstract][Full Text] [Related]
20. The melanocortin 1, 3, 4 or 5 receptors do not have a binding epitope for ACTH beyond the sequence of alpha-MSH.
Schiöth HB; Muceniece R; Larsson M; Wikberg JE
J Endocrinol; 1997 Oct; 155(1):73-8. PubMed ID: 9390008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
